How Diseases Are Inherited Through Genes: A Molecular Overview

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Genetic Inheritance of Disease

Genetic inheritance of disease refers to the transmission of disease-causing genetic variants from parent to offspring through germline cells (sperm or egg). When a mutation is present in a germline cell, every cell of the resulting offspring carries that mutation, which can predispose the individual to, or directly cause, a specific disorder. This contrasts with somatic mutations, which arise spontaneously in non-germline tissues during an individual's lifetime and are not passed to offspring.

The central dogma of molecular biology—DNA → RNA → protein—provides the framework for understanding how mutations cause disease. A mutation in a gene's coding sequence can alter the amino acid sequence of the encoded protein, changing its structure, stability, or function. Alternatively, mutations in regulatory regions can alter when, where, or how much of a protein is produced. The clinical consequence depends on the gene's role, the mutation's severity, and the inheritance pattern that governs how the variant is transmitted.

What Does It Mean for a Disease to Be Inherited?

A disease is inherited when its underlying genetic cause is transmitted through generations according to predictable patterns. Inherited diseases are distinct from acquired genetic diseases, such as most cancers, which arise from somatic mutations accumulated during life. For a disease to be inherited, the causative mutation must be present in the germline—either in one or both alleles of a nuclear gene, or in the mitochondrial genome.

The human genome contains approximately 20,000 protein-coding genes, and mutations in over 4,000 of these are known to cause Mendelian (single-gene) disorders. These disorders follow clear inheritance patterns because the disease phenotype is largely determined by the genotype at a single locus. However, most common diseases—including type 2 diabetes, hypertension, and coronary artery disease—do not follow simple Mendelian inheritance. Instead, they arise from the combined effects of multiple genetic variants, each contributing a small effect, interacting with environmental factors.

Genes, Alleles, and Mutations

A gene is a segment of DNA that contains the instructions for synthesizing a functional product, typically a protein. Each gene occupies a specific location, or locus, on a chromosome. Humans are diploid organisms, meaning we carry two copies of each autosome (chromosomes 1–22) and therefore two alleles—alternative versions—of each gene. The two alleles may be identical (homozygous) or different (heterozygous).

A mutation is a permanent change in the DNA sequence. Mutations can be classified by their effect on the DNA sequence: single nucleotide substitutions (point mutations), insertions or deletions of nucleotides (indels), and larger structural changes such as copy number variations. The functional consequences of these mutations are discussed in detail in Many Different Types of Mutation in Genes. For inherited disease, the critical distinction is whether a mutation is present in the germline and whether it alters protein function in a way that produces a clinical phenotype.

Mendelian Inheritance Patterns

Mendelian inheritance patterns describe disorders caused by mutations in a single gene. These patterns are named after Gregor Mendel, whose work with pea plants established the laws of segregation and independent assortment. Four principal patterns exist: autosomal dominant, autosomal recessive, X-linked dominant, and X-linked recessive.

Autosomal Dominant Disorders

In autosomal dominant disorders, a mutation in a single copy of a gene (heterozygous state) is sufficient to cause the disease. An affected individual has a 50% chance of passing the mutant allele to each offspring. Both males and females are affected equally, and male-to-male transmission occurs, distinguishing autosomal inheritance from X-linked inheritance.

The molecular basis of dominance varies. In many cases, the mutant allele produces a protein with a new, harmful function (gain-of-function), or the mutant protein interferes with the normal protein's function (dominant-negative effect). In other cases, haploinsufficiency occurs: the single normal allele cannot produce enough functional protein to maintain normal physiology.

Classic examples include:

• Huntington's disease: Caused by a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4. The expanded repeat produces a mutant huntingtin protein with an extended polyglutamine tract that aggregates and causes neuronal toxicity.
• Marfan syndrome: Caused by mutations in FBN1, encoding fibrillin-1, a structural component of connective tissue. Most mutations cause haploinsufficiency or dominant-negative effects, leading to tall stature, aortic aneurysms, and lens dislocation.
• Familial hypercholesterolemia: Caused by mutations in LDLR, APOB, or PCSK9. Heterozygous individuals have elevated LDL cholesterol from birth and early atherosclerosis.

Autosomal Recessive Disorders

Autosomal recessive disorders require mutations in both alleles of a gene for disease expression. Heterozygous carriers—individuals with one mutant and one normal allele—are typically asymptomatic. When two carriers have children, each child has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of having two normal alleles.

The molecular basis of recessive disease is almost always loss-of-function: the mutant alleles produce little or no functional protein, and the single normal allele in carriers produces enough protein to maintain normal function (typically 50% of normal levels is sufficient). Recessive disorders are more common in populations with high rates of consanguinity, as related individuals are more likely to carry the same recessive mutations.

Examples include:

• Cystic fibrosis: Caused by mutations in CFTR, encoding the cystic fibrosis transmembrane conductance regulator, a chloride channel. The most common mutation, ΔF508, deletes phenylalanine at position 508, causing misfolding and degradation of the protein before it reaches the cell membrane.
• Sickle cell disease: Caused by a single point mutation (GAG→GTG) in the HBB gene, substituting valine for glutamic acid at position 6 of the β-globin chain. The mutant hemoglobin polymerizes under low oxygen conditions, causing red blood cells to assume a sickle shape.
• Tay-Sachs disease: Caused by mutations in HEXA, encoding the α-subunit of β-hexosaminidase A. Deficiency of this lysosomal enzyme leads to accumulation of GM2 ganglioside in neurons, causing progressive neurodegeneration.

X-Linked Inheritance

X-linked disorders involve genes on the X chromosome. Because males have only one X chromosome (hemizygous), they express all X-linked alleles, whether dominant or recessive. Females have two X chromosomes, but X-inactivation (lyonization) randomly silences one X chromosome in each cell during early embryonic development, creating mosaicism.

X-linked recessive disorders predominantly affect males. Affected males transmit the mutant allele to all daughters (who become carriers) but to no sons (who receive the Y chromosome). Carrier females have a 50% chance of passing the mutant allele to each child; affected sons inherit the mutation from their carrier mothers.

Examples include:

• Hemophilia A: Caused by mutations in F8, encoding coagulation factor VIII. Factor VIII deficiency impairs the intrinsic coagulation pathway, causing prolonged bleeding.
• Duchenne muscular dystrophy: Caused by mutations in DMD, encoding dystrophin, a structural protein linking the cytoskeleton to the extracellular matrix in muscle cells. Most mutations are deletions that abolish dystrophin production, leading to progressive muscle degeneration.
• Red-green color blindness: Caused by mutations in OPN1LW or OPN1MW, encoding long- and medium-wavelength cone opsins.

X-linked dominant disorders affect both males and females, but with different severities. Affected males typically have more severe disease because they lack a second X chromosome to provide a normal allele. Some X-linked dominant disorders are lethal in males, so affected individuals are almost exclusively female.

Examples include:

• Rett syndrome: Caused by mutations in MECP2, encoding methyl-CpG-binding protein 2, a transcriptional regulator. Affected females develop normally for 6–18 months, then experience regression of language and motor skills. Most affected males die in infancy.
• Vitamin D-resistant rickets (X-linked hypophosphatemia): Caused by mutations in PHEX, leading to renal phosphate wasting and rickets.

The following table summarizes the key features of Mendelian inheritance patterns:

Non-Mendelian Inheritance Mechanisms

Not all inherited diseases follow Mendelian rules. Several mechanisms produce inheritance patterns that deviate from the classical patterns, including mitochondrial inheritance, genomic imprinting, and dynamic mutations.

Mitochondrial DNA Inheritance

Mitochondria contain their own circular DNA genome (mtDNA), which is approximately 16.6 kb and encodes 37 genes: 13 protein-coding genes for oxidative phosphorylation complexes, 22 tRNAs, and 2 rRNAs. Mitochondrial DNA is inherited almost exclusively from the mother, because sperm mitochondria are ubiquitinated and degraded after fertilization.

Mitochondrial diseases exhibit maternal inheritance: affected mothers transmit the disorder to all children, but affected fathers do not transmit it to any children. Because each cell contains hundreds to thousands of mitochondria, a mutation may be present in all mitochondria (homoplasmy) or in a mixture of mutant and normal mitochondria (heteroplasmy). The clinical phenotype depends on the proportion of mutant mtDNA in affected tissues, a concept called the threshold effect.

Examples include:

• Leber hereditary optic neuropathy (LHON): Caused by point mutations in mtDNA genes encoding complex I subunits (e.g., MT-ND4 at position 11778). The mutation causes acute or subacute bilateral vision loss in young adults.
• MELAS syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes): Most commonly caused by the m.3243A>G mutation in the MT-TL1 gene encoding tRNA^Leu(UUR). The mutation impairs mitochondrial protein synthesis, reducing ATP production.

Genomic Imprinting

Genomic imprinting is an epigenetic phenomenon in which certain genes are expressed only from the maternal or paternal allele, not both. Imprinting is established during gametogenesis through DNA methylation at imprinting control regions, and it is maintained through mitosis in somatic cells. The molecular mechanisms are discussed in Epigenetics Inherited.

When an imprinted gene is mutated or deleted, the clinical outcome depends on which parent contributed the mutant allele. If the expressed allele is mutated, disease results; if the silenced allele is mutated, the individual is typically unaffected.

Examples include:

• Prader-Willi syndrome: Caused by loss of function of paternally expressed genes on chromosome 15q11-q13 (e.g., SNRPN, NDN). This can result from paternal deletion, maternal uniparental disomy (both copies of chromosome 15 from the mother), or imprinting defects. Features include neonatal hypotonia, hyperphagia, and obesity.
• Angelman syndrome: Caused by loss of function of the maternally expressed gene UBE3A on chromosome 15q11-q13. This can result from maternal deletion, paternal uniparental disomy, or mutations in UBE3A. Features include severe intellectual disability, seizures, and a happy demeanor.

Dynamic Mutations

Dynamic mutations are unstable expansions of trinucleotide or other short tandem repeats that can expand further between generations. The repeat number can increase during meiosis, particularly in males, leading to anticipation—earlier onset and increased severity in successive generations.

The molecular mechanism depends on the repeat's location:

• Coding region expansions (e.g., CAG repeats in Huntington's disease, spinocerebellar ataxias): The expanded repeat produces a protein with an elongated polyglutamine tract, which misfolds and aggregates.
• Non-coding expansions (e.g., FMR1 in fragile X syndrome, DMPK in myotonic dystrophy): The expansion silences the gene or produces toxic RNA.

For example, in fragile X syndrome, unaffected individuals have 5–44 CGG repeats in the 5' untranslated region of FMR1. Premutation carriers have 55–200 repeats, and full mutations (>200 repeats) cause hypermethylation and transcriptional silencing of FMR1, leading to loss of FMRP, an RNA-binding protein essential for synaptic plasticity.

Molecular Basis of Inherited Mutations

The types of mutations that cause inherited disease are diverse, and their effects on protein function depend on the mutation's nature and location within the gene.

Types of Gene Mutations

Point mutations are single nucleotide substitutions. They fall into three categories:

• Missense mutations: Change one amino acid to another. The effect depends on the chemical difference between the original and substituted amino acid. For example, in sickle cell disease, the substitution of valine (hydrophobic) for glutamic acid (charged) at position 6 of β-globin creates a hydrophobic patch that drives hemoglobin polymerization.
• Nonsense mutations: Introduce a premature stop codon, leading to a truncated protein. Nonsense-mediated mRNA decay often degrades the mutant transcript, resulting in loss-of-function.
• Silent mutations: Do not change the amino acid sequence due to the degeneracy of the genetic code. These are usually benign, though they can affect splicing if they occur at splice sites or create cryptic splice sites.

Frameshift mutations are insertions or deletions of nucleotides that are not multiples of three. They shift the reading frame, producing a completely different amino acid sequence downstream of the mutation and typically introducing a premature stop codon. The consequences are almost always severe loss-of-function. Detailed mechanisms are covered in Frameshift Mutation.

Copy number variations (CNVs) are deletions or duplications of DNA segments larger than 1 kb. They can remove entire genes, duplicate genes, or disrupt regulatory regions. For example, most cases of Charcot-Marie-Tooth disease type 1A result from a 1.4 Mb duplication of chromosome 17p12, which includes PMP22, encoding peripheral myelin protein 22. The extra copy causes overexpression of PMP22, which is toxic to Schwann cells.

Loss-of-Function vs. Gain-of-Function

Mutations can be classified by their effect on protein function:

Loss-of-function mutations reduce or eliminate protein function. These are typically recessive, because the remaining normal allele can often produce sufficient protein. However, haploinsufficiency—where 50% of normal protein levels are insufficient—can cause dominant disease. Examples include LDLR mutations in familial hypercholesterolemia and COL5A1 mutations in Ehlers-Danlos syndrome.

Gain-of-function mutations confer new or enhanced activity on the protein. These are typically dominant, because the mutant allele produces a harmful product regardless of the normal allele. Examples include:

• **Activating mutations in RET** causing multiple endocrine neoplasia type 2: The mutant RET receptor tyrosine kinase is constitutively active, driving uncontrolled cell proliferation.
• **Oncogenic mutations in RAS family genes**: Mutations at codons 12, 13, or 61 lock RAS in the active GTP-bound state, promoting continuous downstream signaling. These are somatic in most cancers, but germline mutations cause RASopathies such as Noonan syndrome.

Dominant-negative mutations produce a mutant protein that interferes with the normal protein's function, often by forming nonfunctional multimers. For example, in osteogenesis imperfecta, mutations in COL1A1 or COL1A2 produce abnormal collagen chains that incorporate into triple helices, disrupting the entire collagen fibril.

Complex and Multifactorial Inheritance

Most common diseases do not follow Mendelian patterns. Instead, they are complex traits influenced by multiple genes, each with small effects, and environmental factors. These are sometimes called multifactorial or polygenic disorders.

Polygenic Risk Scores

A polygenic risk score (PRS) aggregates the effects of many genetic variants across the genome into a single number that estimates an individual's genetic predisposition to a disease. Each variant is assigned a weight based on its effect size, typically derived from genome-wide association studies (GWAS). The PRS is calculated as the sum of risk alleles carried, weighted by their effect sizes.

For example, in type 2 diabetes, over 400 independent genetic loci have been associated with disease risk. The strongest single variant, in TCF7L2, increases risk by approximately 1.4-fold per allele. However, most variants have odds ratios between 1.05 and 1.15. A PRS combining these variants can stratify individuals into risk categories, though the clinical utility remains limited because the PRS explains only a fraction of heritability.

The heritability of complex diseases—the proportion of phenotypic variance attributable to genetic variation—varies widely. For type 2 diabetes, heritability is estimated at 30–40%; for schizophrenia, 60–80%; for height, 80%. The "missing heritability" problem refers to the gap between heritability estimated from family studies and the variance explained by identified genetic variants.

Gene-Environment Interactions

Gene-environment interactions occur when the effect of a genetic variant on disease risk depends on environmental exposure. These interactions complicate the study of complex diseases because the same genotype can produce different phenotypes in different environments.

A well-characterized example is the interaction between FTO variants and physical activity in obesity. The FTO risk allele (rs9939609) is associated with increased body mass index, but this effect is attenuated by approximately 30% in physically active individuals compared to sedentary individuals.

Another example is phenylketonuria (PKU), a Mendelian disorder that illustrates gene-environment interaction. Mutations in PAH, encoding phenylalanine hydroxylase, cause accumulation of phenylalanine and severe intellectual disability. However, if affected individuals adhere to a low-phenylalanine diet from birth, they develop normally. The disease phenotype is thus determined by both genotype and diet.

Methods for Studying Inherited Diseases

Identifying the genetic basis of inherited diseases requires multiple approaches, from classical family studies to modern high-throughput sequencing.

Pedigree Analysis

Pedigree analysis is the systematic study of a family's medical history to determine the mode of inheritance. A pedigree is a standardized diagram using symbols: squares for males, circles for females, filled symbols for affected individuals, and half-filled symbols for carriers.

Key features to examine include:

• Vertical transmission (affected individuals in every generation) suggests dominant inheritance.
• Horizontal transmission (affected individuals in one generation, with carrier parents) suggests recessive inheritance.
• Sex distribution distinguishes autosomal from X-linked patterns.
• Male-to-male transmission excludes X-linked inheritance.

Pedigree analysis remains essential for genetic counseling and for classifying families before molecular testing.

Genome-Wide Association Studies

Genome-wide association studies (GWAS) compare the frequency of hundreds of thousands to millions of single nucleotide polymorphisms (SNPs) between cases and controls. The goal is to identify variants associated with disease risk. GWAS are powered to detect common variants (minor allele frequency >5%) with modest effect sizes.

A typical GWAS workflow:

1. Genotype cases and controls using SNP arrays or low-pass whole-genome sequencing.
2. Perform quality control: exclude SNPs with low call rates, Hardy-Weinberg equilibrium deviations, or low minor allele frequency.
3. Test each SNP for association using logistic regression, adjusting for population stratification (principal components) and covariates.
4. Apply a genome-wide significance threshold of p < 5 × 10⁻⁸ to account for multiple testing.
5. Replicate findings in independent cohorts.

GWAS have identified thousands of disease-associated loci. However, most associated variants are in non-coding regions, and identifying the causal gene and mechanism requires functional follow-up studies. The results are often visualized using Manhattan plots and regional association plots, which can be explored using tools like Heat Map of Genes and Heatmap of Differentially Expressed Genes.

DNA Sequencing Technologies

Sanger sequencing was the first widely used method for identifying disease-causing mutations. It uses chain-terminating dideoxynucleotides to generate fragments of different lengths, which are separated by capillary electrophoresis. Sanger sequencing has a read length of 600–1000 bp and is still used for targeted sequencing of single genes or small panels.

Next-generation sequencing (NGS) technologies enable massively parallel sequencing of millions of DNA fragments simultaneously. Key platforms include:

• Illumina sequencing: Uses bridge amplification and reversible terminator chemistry. Typical read lengths are 150 bp paired-end, with throughput of up to 6 Tb per run on the NovaSeq platform.
• Ion Torrent: Detects hydrogen ions released during nucleotide incorporation, using semiconductor technology.

NGS applications include:

• Whole-exome sequencing: Targets the ~1.5% of the genome that codes for proteins. The exome is captured using hybridization probes, then sequenced at high depth (typically 100×).
• Whole-genome sequencing: Sequences the entire genome at 30× coverage, detecting coding and non-coding variants, structural variants, and repeat expansions.
• Targeted gene panels: Sequence a curated set of genes known to cause a specific phenotype, offering higher depth and lower cost.

For variant detection, bioinformatics pipelines align reads to the reference genome (GRCh38), call variants using tools like GATK HaplotypeCaller, and annotate variants using databases such as ClinVar and gnomAD.

Genetic Testing and Counseling

Genetic testing identifies mutations associated with inherited diseases, enabling diagnosis, prediction, and reproductive planning.

Types of Genetic Tests

Diagnostic testing confirms or rules out a suspected genetic disorder in a symptomatic individual. For example, sequencing CFTR in a patient with elevated sweat chloride confirms cystic fibrosis.

Predictive testing identifies asymptomatic individuals at risk for a genetic disorder. This is used for adult-onset conditions such as Huntington's disease or hereditary cancer syndromes. Predictive testing requires careful counseling because a positive result can have profound psychological and social consequences.

Carrier testing identifies individuals who carry one copy of a recessive mutation. This is offered to individuals with a family history of recessive disorders or to populations with high carrier frequencies, such as CFTR testing in individuals of Northern European descent or HBB testing in individuals of African, Mediterranean, or Southeast Asian descent.

Prenatal testing detects genetic disorders in a fetus. Methods include chorionic villus sampling (10–12 weeks gestation) and amniocentesis (15–20 weeks gestation). Cell-free fetal DNA testing (non-invasive prenatal testing) analyzes fetal DNA in maternal blood and can screen for common aneuploidies.

Preimplantation genetic testing is performed on embryos created by in vitro fertilization before implantation. Embryos are biopsied at the blastocyst stage (5–6 days), and cells are analyzed for the specific mutation or chromosomal abnormality.

Ethical Considerations

Genetic testing raises significant ethical issues:

• Informed consent: Patients must understand the purpose, limitations, and potential consequences of testing before providing consent.
• Privacy and confidentiality: Genetic information is sensitive and can affect employment, insurance, and family relationships. The Genetic Information Nondiscrimination Act (GINA, 2008) prohibits health insurers and employers from discriminating based on genetic information in the United States.
• Reproductive autonomy: Prenatal and preimplantation testing can lead to difficult decisions about pregnancy termination or embryo selection.
• Incidental findings: Sequencing may reveal mutations unrelated to the test indication, such as a BRCA1 mutation found during exome sequencing for a neurological disorder. Policies vary on whether and how to report these findings.
• Psychological impact: Predictive testing for untreatable conditions, such as Huntington's disease, can cause anxiety, depression, and stigma.

Common Pitfalls and Misconceptions

Students frequently encounter several conceptual errors when studying genetic inheritance.

Dominant Does Not Mean More Common

A dominant allele is defined by its effect on phenotype in the heterozygous state, not by its frequency in the population. Many dominant disorders are rare because the mutations reduce reproductive fitness. Conversely, some recessive alleles are common because carriers have no phenotype and may even have a selective advantage. The classic example is the sickle cell allele, which reaches frequencies of 20–30% in malaria-endemic regions because heterozygotes are protected against severe malaria.

Penetrance and Expressivity

Penetrance is the proportion of individuals with a disease-causing genotype who express the phenotype. Reduced penetrance means some individuals with the mutation do not develop disease. For example, BRCA1 mutations have approximately 70% penetrance for breast cancer by age 80, meaning 30% of carriers never develop breast cancer.

Expressivity refers to the variability in phenotype severity among individuals with the same genotype. For example, neurofibromatosis type 1, caused by NF1 mutations, shows highly variable expressivity: some affected individuals have only café-au-lait spots, while others develop plexiform neurofibromas, optic gliomas, and skeletal abnormalities.

Penetrance and expressivity are influenced by modifier genes, environmental factors, and stochastic events. They complicate genotype-phenotype correlations and genetic counseling.

Mistaking Somatic for Germline Mutations

Somatic mutations arise in non-germline tissues and are not inherited. They are the basis of most cancers, which are genetic diseases at the cellular level but not inherited diseases at the organismal level. However, germline mutations in genes such as TP53 (Li-Fraumeni syndrome), BRCA1/BRCA2 (hereditary breast and ovarian cancer), and APC (familial adenomatous polyposis) predispose individuals to cancer by increasing the likelihood of somatic mutations in tumor suppressor genes or oncogenes. The distinction between germline and somatic mutations is critical: germline mutations are present in every cell and can be passed to offspring, while somatic mutations are confined to the affected tissue. The role of tumor suppressor genes in inherited cancer syndromes is discussed in Tumor Suppressor Gene.

Frequently Asked Questions

Can diseases be inherited through genes?

Yes. Diseases can be inherited when disease-causing mutations are present in germline cells (sperm or egg) and are transmitted to offspring. These mutations are present in every cell of the offspring and can cause disease directly or increase susceptibility to disease. Inherited diseases follow patterns such as autosomal dominant, autosomal recessive, X-linked, mitochondrial, or multifactorial inheritance.

What are the main patterns of genetic inheritance?

The main patterns are: autosomal dominant (one mutant allele sufficient), autosomal recessive (two mutant alleles required), X-linked recessive (predominantly affects males), X-linked dominant (affects both sexes, often more severe in males), mitochondrial (maternal inheritance), and multifactorial (multiple genes plus environment). Each pattern has characteristic pedigree features that aid in diagnosis.

How do mutations cause inherited diseases?

Mutations cause disease by altering protein function. Loss-of-function mutations reduce or eliminate protein activity, often causing recessive disease. Gain-of-function mutations confer new or enhanced activity, typically causing dominant disease. Dominant-negative mutations produce proteins that interfere with normal protein function. The specific mechanism depends on the mutation type (point, frameshift, copy number) and the gene's role.

Are all inherited diseases present from birth?

No. While the genetic mutation is present from conception, the disease phenotype may not manifest until later in life. Huntington's disease typically presents in mid-adulthood, hereditary hemochromatosis in the fourth to fifth decade, and some inherited cancer syndromes have variable age of onset. Some disorders, such as congenital adrenal hyperplasia, present in infancy, while others, like Alzheimer's disease associated with APOE ε4, have late onset.

What is the difference between inherited and genetic diseases?

All inherited diseases are genetic, but not all genetic diseases are inherited. Genetic diseases include both germline mutations (inherited) and somatic mutations (acquired during life, such as most cancers). Inherited diseases are present in the germline and can be transmitted to offspring. Somatic mutations are not transmitted. Additionally, some genetic diseases arise from de novo mutations—new mutations in the germline of a parent or in the early embryo—that are not present in either parent's somatic cells.

Can complex diseases like diabetes be inherited?

Yes, complex diseases have a genetic component, but they do not follow Mendelian inheritance patterns. Type 2 diabetes, hypertension, coronary artery disease, and many psychiatric disorders are polygenic: they result from the combined effects of many genetic variants, each with small effect, interacting with environmental factors. Family history is a risk factor, but the inheritance pattern is not predictable in individual families. Polygenic risk scores can estimate genetic predisposition, but they do not provide definitive diagnoses.

How are inherited diseases diagnosed?

Inherited diseases are diagnosed through a combination of clinical evaluation, family history (pedigree analysis), biochemical tests, and genetic testing. Genetic testing methods include targeted mutation analysis, gene panel sequencing, whole-exome sequencing, and whole-genome sequencing. Prenatal diagnosis is possible through chorionic villus sampling, amniocentesis, or non-invasive prenatal testing. Genetic counseling is recommended before and after testing to explain results and implications.

Key Takeaways

• Inherited diseases arise from germline mutations transmitted from parent to offspring, and they follow predictable patterns: autosomal dominant, autosomal recessive, X-linked, mitochondrial, or multifactorial.
• Autosomal dominant disorders require only one mutant allele and often involve gain-of-function or dominant-negative mechanisms; autosomal recessive disorders require two mutant alleles and typically involve loss-of-function.
• X-linked disorders predominantly affect males in recessive patterns, while mitochondrial disorders are transmitted exclusively through the mother.
• Non-Mendelian mechanisms include genomic imprinting (parent-of-origin effects), dynamic mutations (trinucleotide repeat expansions with anticipation), and mitochondrial heteroplasmy.
• Mutation types—point, frameshift, and copy number variants—determine the molecular consequence: loss-of-function, gain-of-function, or dominant-negative effects on protein function.
• Complex diseases are polygenic and multifactorial; polygenic risk scores aggregate small-effect variants, but gene-environment interactions complicate risk prediction.
• Modern diagnosis relies on pedigree analysis, GWAS, and next-generation sequencing, with genetic counseling essential for interpreting results and addressing ethical considerations.

Further Reading

• Schneider N et al. Inherited retinal diseases: Linking genes, disease-causing variants, and relevant therapeutic modalities. Progress in retinal and eye research. 2022. PubMed 34839010
• Jimenez-Sanchez G, Childs B, Valle D. Human disease genes. Nature. 2001. PubMed 11237009
• Viscomi C, Zeviani M. MtDNA-maintenance defects: syndromes and genes. Journal of inherited metabolic disease. 2017. PubMed 28324239

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks